Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 9/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32685345 | 1.00 | PRKCQ (0.53) | PRKCQPRKCDHDAC1NMT1TRPV1 | |
| SCHEMBL32685368 | 1.00 | PRKCQ (0.53) | PRKCQPRKCDHDAC1NMT1TRPV1 | |
| SCHEMBL4795035 | 0.91 | PRKCQ (0.46) | PRKCQPRKCDHDAC1ZAP70 | |
| SCHEMBL32685342 | 0.82 | PRKCQ (0.49) | PRKCQPRKCDHDAC1TRPV1 | |
| SCHEMBL32685347 | 0.82 | PRKCQ (0.49) | PRKCQPRKCDHDAC1TRPV1 | |
| SCHEMBL32685344 | 0.82 | PRKCQ (0.49) | PRKCQPRKCDHDAC1TRPV1 | |
| SCHEMBL14258699 | 0.79 | HDAC1 (0.44) | PRKCQPRKCDHDAC1NMT1ZAP70 | |
| SCHEMBL4775881 | 0.78 | BPTF (0.55) | PRKCQPRKCDHDAC1 | |
| SCHEMBL4725933 | 0.78 | HDAC1 (0.43) | PRKCQPRKCDHDAC1NMT1ZAP70 | |
| SCHEMBL4725434 | 0.78 | HDAC1 (0.48) | PRKCQPRKCDHDAC1NMT1ZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | PRKCQ 2919/4885PRKCD 2970/4885HDAC1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.